ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability‐high (MSI‐H) molecular subtype

Melica Nourmoussavi Brodeur,Pier Selenica,Weining Ma,Sara Moufarrij,Christian Dagher,Thais Basili,Nadeem R. Abu‐Rustum,Carol Aghajanian,Qin Zhou,Alexia Iasonos,Lora H. Ellenson,Britta Weigelt,M. Herman Chui

DOI: https://doi.org/10.1002/1878-0261.13698

2024-07-20

Molecular Oncology

Abstract:ERBB2 amplification is a known driver of copy number‐high/TP53‐abnormal high‐grade endometrial carcinoma and is associated with HER2 overexpression. In this retrospective cohort of clinically annotated endometrial carcinomas, ERBB2 pathogenic mutations define a distinct and non‐overlapping subgroup of tumors, typically with low levels of HER2 expression, high tumor mutational burden, microsatellite instability‐high status, and low‐grade endometrioid histology. Anti‐HER2 therapy is indicated for erb‐b2 receptor tyrosine kinase 2 (ERBB2)‐amplified/overexpressing endometrial carcinoma (EC). Mutations constitute another mode of ERBB2 activation, but only rare ERBB2‐mutated ECs have been reported. We sought to characterize the clinicopathologic and genetic features of ERBB2‐mutated EC. From an institutional cohort of 2638 ECs subjected to clinical tumor‐normal panel sequencing, 69 (2.6%) with pathogenic ERBB2 mutation(s) were identified, of which 11 were also ERBB2‐amplified. The most frequent ERBB2 hotspot mutations were V842I (38%) and R678Q (25%). ERBB2 mutations were clonal in 87% of evaluable cases. Immunohistochemistry revealed low HER2 protein expression in most ERBB2‐mutated ECs (0/1+ in 66%, 2+ in 27%); all 3+ tumors (7.3%) were also ERBB2‐amplified. Compared to ERBB2‐wildtype ECs (with or without ERBB2 amplification), ERBB2‐mutated/non‐amplified ECs were enriched for the microsatellite instability‐high (MSI‐H) and, to a lesser extent, DNA polymerase epsilon, catalytic subunit (POLE) molecular subtypes, and associated with high tumor mutational burden and low chromosomal instability. Survival outcomes were similar between patients with ERBB2‐mutated/non‐amplified versus wildtype EC, whereas ERBB2 amplification was associated with worse prognosis on univariate, but not multivariate, analyses. In conclusion, ERBB2 mutation defines a rare subgroup of ECs that is pathogenically distinct from ERBB2‐wildtype and ERBB2‐amplified ECs.

oncology